- Home
- GNTA vs HOWL Comparison
GNTA vs HOWL Comparison
Compare GNTA & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- HOWL
- Stock Information
- Founded
- GNTA 2014
- HOWL 2017
- Country
- GNTA Italy
- HOWL United States
- Employees
- GNTA N/A
- HOWL N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- HOWL Health Care
- Exchange
- GNTA Nasdaq
- HOWL Nasdaq
- Market Cap
- GNTA 59.7M
- HOWL 64.5M
- IPO Year
- GNTA 2021
- HOWL 2021
- Fundamental
- Price
- GNTA $3.23
- HOWL $1.95
- Analyst Decision
- GNTA
- HOWL Strong Buy
- Analyst Count
- GNTA 0
- HOWL 5
- Target Price
- GNTA N/A
- HOWL $7.20
- AVG Volume (30 Days)
- GNTA 14.3K
- HOWL 1.1M
- Earning Date
- GNTA 01-01-0001
- HOWL 11-06-2025
- Dividend Yield
- GNTA N/A
- HOWL N/A
- EPS Growth
- GNTA N/A
- HOWL N/A
- EPS
- GNTA N/A
- HOWL N/A
- Revenue
- GNTA N/A
- HOWL N/A
- Revenue This Year
- GNTA N/A
- HOWL N/A
- Revenue Next Year
- GNTA N/A
- HOWL N/A
- P/E Ratio
- GNTA N/A
- HOWL N/A
- Revenue Growth
- GNTA N/A
- HOWL N/A
- 52 Week Low
- GNTA $2.56
- HOWL $0.60
- 52 Week High
- GNTA $7.28
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- GNTA 49.34
- HOWL 68.99
- Support Level
- GNTA $2.99
- HOWL $1.92
- Resistance Level
- GNTA $3.22
- HOWL $2.15
- Average True Range (ATR)
- GNTA 0.22
- HOWL 0.17
- MACD
- GNTA 0.04
- HOWL 0.05
- Stochastic Oscillator
- GNTA 71.48
- HOWL 69.23
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.